Stephen Clarke

Active 1979–2024

146
Papers
24,638
Citations
81
h-index
139
i10-index

Citations

Citations per year for Stephen Clarke1971: 1 citations1980: 2 citations1981: 2 citations1982: 2 citations1983: 3 citations1984: 3 citations1985: 1 citations1986: 1 citations1987: 3 citations1988: 2 citations1989: 2 citations1990: 4 citations1991: 4 citations1992: 5 citations1993: 11 citations1994: 5 citations1995: 3 citations1996: 2 citations1997: 7 citations1998: 6 citations1999: 7 citations2000: 5 citations2001: 5 citations2002: 7 citations2003: 11 citations2004: 25 citations2005: 42 citations2006: 45 citations2007: 37 citations2008: 91 citations2009: 106 citations2010: 138 citations2011: 145 citations2012: 178 citations2013: 183 citations2014: 240 citations2015: 178 citations2016: 188 citations2017: 213 citations2018: 199 citations2019: 881 citations2020: 994 citations2021: 1,006 citations2022: 741 citations2023: 547 citations2024: 838 citations2025: 394 citations2026: 7 citations1972–1979: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,044 citing papers, 19.2% of this breakdownChina: 1,621 citing papers, 15.2% of this breakdownUnited Kingdom: 687 citing papers, 6.5% of this breakdownItaly: 599 citing papers, 5.6% of this breakdownAustralia: 527 citing papers, 5% of this breakdownGermany: 480 citing papers, 4.5% of this breakdownJapan: 438 citing papers, 4.1% of this breakdownFrance: 367 citing papers, 3.4% of this breakdownCanada: 338 citing papers, 3.2% of this breakdownNetherlands: 338 citing papers, 3.2% of this breakdownSpain: 299 citing papers, 2.8% of this breakdownSouth Korea: 242 citing papers, 2.3% of this breakdown
0%19.2%Other 25%

Fields

  • Medicine70.1%
  • Biochemistry, Genetics and Molecular Biology17.6%
  • Immunology and Microbiology3.3%
  • Pharmacology, Toxicology and Pharmaceutics1.5%
  • Materials Science1.2%
  • Neuroscience1%
  • Other5.3%

Topics

  • Inflammatory Biomarkers in Disease Prognosis6.3%
  • Cancer Immunotherapy and Biomarkers3.3%
  • Colorectal Cancer Treatments and Studies3.3%
  • Colorectal Cancer Surgical Treatments2%
  • Lung Cancer Treatments and Mutations2%
  • Cancer survivorship and care1.8%
  • Other81.3%

Coauthors

All papers

Open in search
  1. Cancer-related inflammation and treatment effectiveness

    Authors: , , , - The Lancet Oncology 2014 cited by 2,187

  2. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study

    Authors: , , , , , , , , , , , , , , , , - The Lancet Oncology 2017 cited by 709

  3. The systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancer

    Authors: , , , , , - Critical Reviews in Oncology/Hematology 2013 cited by 1,539

  4. Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2018 cited by 559

  5. Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kenneth Ng, Juliana Eng, Isabel R. Preeshagul, W. Victoria Lai, John J. Fiore, Afsheen N. Iqbal, Daniela Molena, Gaetano Rocco, Bernard J. Park, Lee P. Lim, Mark Junjie Li, Candace Tong-Li, Madhawa De Silva, David Chan, Connie I. Diakos, Malinda Itchins, Stephen Clarke, Nick Pavlakis, Adrian V. Lee, Natasha Rekhtman, Jason C. Chang, William D. Travis, Gregory J. Riely, David B. Solit, Mithat Gönen, Valerie W. Rusch, Andreas Rimner, Daniel R. Gomez, Alexander Drilon, Howard I. Scher, Sohrab P. Shah, Michael F. Berger, Maria E. Arcila, Marc Ladanyi, Ross L. Levine, Ronglai Shen, Pedram Razavi, Jorge S. Reis‐Filho, David R. Jones, Charles M. Rudin, James M. Isbell, Bob T. Li - Nature Medicine 2022 cited by 185

  6. First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Cancer Immunology Immunotherapy 2023 cited by 109

  7. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

    Authors: , , , , , , , , , , , , - Journal of Clinical Oncology 2008 cited by 2,963

  8. Clinical Development of TargomiRs, a miRNA Mimic-Based Treatment for Patients with Recurrent Thoracic Cancer

    Authors: , , , , , , , - Epigenomics 2016 cited by 230

  9. Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance

    Authors: , , , , , , , , , , , , , , - Theranostics 2017 cited by 286

  10. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2020 cited by 153

  11. The Lymphocyte-to-Monocyte Ratio is a Superior Predictor of Overall Survival in Comparison to Established Biomarkers of Resectable Colorectal Cancer

    Authors: , , , , , , - Annals of Surgery 2016 cited by 302

  12. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sing Yu Moorcraft, Ken‐ichi Okada, Alessandro Paniccia, Parag J. Parikh, Niek A. Peters, Hans Rabl, Jaswinder S. Samra, Christoph Tinchon, Geertjan van Tienhoven, Eran van Veldhuisen, Andrea Wang‐Gillam, Matthew J. Weiss, Johanna W. Wilmink, Hiroki Yamaue, Marjolein Y.V. Homs, Casper H.J. van Eijck, Matthew H. G. Katz, Bas Groot Koerkamp - JNCI Journal of the National Cancer Institute 2019 cited by 295

  13. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

    Authors: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2012 cited by 526

  14. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer

    Authors: , , , , , - British Journal of Cancer 2012 cited by 519

  15. Cognitive Function in Patients With Colorectal Cancer Who Do and Do Not Receive Chemotherapy: A Prospective, Longitudinal, Controlled Study

    Authors: , , , , , , , , , , - Journal of Clinical Oncology 2015 cited by 265

  16. Activation of Thermogenesis in Brown Adipose Tissue and Dysregulated Lipid Metabolism Associated with Cancer Cachexia in Mice

    Authors: , , , , , , , , , , , - Cancer Research 2012 cited by 167

  17. Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer

    Authors: , , , , , , , , , , , , - Journal of Clinical Oncology 2008 cited by 864

  18. The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?

    Authors: , , , , , , , , , , , , , , , , , - Cancers 2021 cited by 62

  19. Cyto-Immuno-Therapy for Cancer: A Pathway Elicited by Tumor-Targeted, Cytotoxic Drug-Packaged Bacterially Derived Nanocells

    Authors: , , , , , , , , , , , , - Cancer Cell 2020 cited by 61

  20. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Joanne Hornbuckle, F. Lofts, Sarah Lowndes, Astrid Mayer, Matthew S. Metcalfe, Gary Middleton, Jamie Mills, Amir Montazeri, R. Muirhead, Andreas Polychronis, Colin Purcell, Paul J. Ross, Ricky A. Sharma, Liz Sherwin, David Smith, Rubin Soomal, Daniel Swinson, Axel Walther, Harpreet Wasan, Andrew Weaver, Charles Wilson, Greg Wilson, Pradip Amin, Bruna Angelelli, Jacques Balosso, Alex Beny, Daniel Bloomgarden, Evelyn Boucher, Michael D. Brown, Harald-Robert Bruch, James Bui, Matthew Burge, Giuseppe Cardaci, James Carlisle, Seungjean Chai, Yi‐Jen Chen, P. Chevallier, Michael Chuong, Stephen Clarke, Andrew L. Coveler, M Craninx, Thierry Delanoit, Amélie Deleporte, Paul Eliadis, Francis Facchini, Thomas W. Ferguson, Michel Ferrante, Michael Findlay, Gary Frenette, Jacob Frick, Vinod Ganju, Michael Garofalo, Karen Geboes, Gerald Gehbauer, Benjamin George, Ravit Geva, Peter Gibbs, Melita A. Gordon, Kate Gregory, Seza A. Güleç, James Hannigan, Guy van Hazel, Norman Heching, Volker Heinemann, Thomas Helmberger, Alain Hendlisz, Koen Hendrickx, Matthew P. Holtzman, Richard Isaacs, Christopher Jackson and 156 more - The Lancet Oncology 2017 cited by 398

  21. Cancer Patient Disclosure and Patient-Doctor Communication of Complementary and Alternative Medicine Use: A Systematic Review

    Authors: , , , , - The Oncologist 2012 cited by 348

  22. Oxidative stress in prostate cancer patients: A systematic review of case control studies

    Authors: , , , , , , , , , , - Prostate International 2016 cited by 101

  23. Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review

    Authors: , , , , , , , , , , , , , , , , , - Frontiers in Oncology 2021 cited by 60

  24. The Cambridge Handbook of Information and Computer Ethics

    Authors: , , , , , , , , , , , , , , , , , , - Cambridge University Press eBooks 2010 cited by 208